Skip to content
Peptigraph home

Thymosin Alpha-1 for Immune System: What the Evidence Shows

What human and animal studies show about Thymosin Alpha-1 for immune system, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureImmune modulatorUpdated
Strongest evidence
Human RCT
Human studies
222
PubMed records, our ledger
Animal studies
101
PubMed records, our ledger
Studies we summarised
10
with an outcome for immune system

Evidence for immune system

Each row is an outcome related to immune system from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Thymosin Alpha-1 for immune system: outcomes in published studies
OutcomeResultStudy typeSource
28-day all-cause mortality28-day mortality was 23.4% on thymosin alpha 1 and 24.1% on placebo (hazard ratio 0.99, P=0.93).Human RCTn = 1106BMJ 2025, PMID 39814420
Safety and secondary outcomesNo secondary or safety outcome differed significantly from placebo.Human RCTn = 1106BMJ 2025, PMID 39814420
Infection rate and ICU stayCulture-positive rates and ICU stay were lower with thymosin alpha 1.Human RCTn = 24Inflammation 2011, PMID 20549321
Non-recovery rateAfter adjustment, thymosin alpha 1 use was associated with a higher non-recovery rate (OR 1.5); sicker patients were more likely to be treated.Human observationaln = 2282Frontiers in immunology 2021, PMID 34408744
CD4+ T cell recoveryCD4+ and CD8+ T cell increases did not differ between treated and untreated groups (p=0.851 and p=0.842).Human observationaln = 275Frontiers in immunology 2021, PMID 34149679
28-day mortality in critical typeIn the critical-type subgroup, thymosin alpha 1 was associated with lower 28-day mortality (HR 0.11, P=0.013).Human observationaln = 334International immunopharmacology 2020, PMID 32795897
All-cause mortalityPooled all-cause mortality was lower (RR 0.53) but certainty is very low.Meta-analysisn = 1349The Cochrane database of systematic reviews 2026, PMID 42713852
28-day mortality (all RCTs)Pooling all included RCTs, thymosin alpha 1 reduced 28-day mortality (OR 0.73, P = 0.003).Meta-analysisn = 1927Frontiers in cellular and infection microbiology 2025, PMID 40969554
High-quality and multicentre trialsHigh-quality (OR 0.82) and multicentre (OR 0.86) subgroups showed no significant mortality benefit.Meta-analysisn = 1927Frontiers in cellular and infection microbiology 2025, PMID 40969554
COVID-19 mortalityMortality was lower (RR 0.59, p = 0.02) but ventilation need and hospital stay did not differ; heterogeneity was high.Meta-analysisInflammopharmacology 2023, PMID 37845598
COVID-19 mortalityOverall mortality did not differ (RR 1.03, p = 0.92); the authors do not support use in hospitalized adults.Meta-analysisn = 5352International immunopharmacology 2023, PMID 36527881
MortalityPooled mortality was lower with thymosin alpha 1 (RR 0.59, p = 0.0001); the authors rate the evidence as low quality.Meta-analysisn = 530BMC infectious diseases 2016, PMID 27633969

PubMed records for Thymosin Alpha-1 and immune system: 222 human, 101 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4BMJ 2025, PMID 39814420

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What the immune system does

Per MedlinePlus, the immune system is a web of cells, tissues and organs working together against infection and disease.[11]

In an autoimmune disease the immune system attacks the body's own healthy cells, which is a different problem from a weak immune system.[12]

What the trials measured: deaths, not general immunity

PubMed counts 222 human-only and 101 animal papers on thymosin alpha 1 with immune terms, including 42 tagged randomized trials.

Calculated from pubmed query ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (immune[tiab] OR immunity[tiab] OR immunomodulat*[tiab] OR immunodefic*[tiab] OR immunostimul*[tiab]); date 2026-10-02; human filter count 305; human only count 222; animal filter count 101; randomized filter count 42. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human, animal and RCT filters shown)

A phase 3 trial in adults with sepsis found 28-day mortality of 23.4% on thymosin alpha 1 against 24.1% on placebo.[1]

A meta-analysis of sepsis trials found no mortality benefit in its high-quality (OR 0.82, p = 0.09) or multi-center (OR 0.86, p = 0.20) subgroups.[7]

For COVID-19, one meta-analysis found lower mortality with thymosin alpha-1 in moderate to critical patients.[8]

A second COVID-19 meta-analysis found no statistically significant effect on mortality (RR 1.03, p = 0.92).[9]

A COVID-19 cohort study reported that, after adjusting for confounding factors, thymosin alpha 1 use was associated with a higher non-recovery rate (OR 1.5).[3]

Looking at immune cells directly, a COVID-19 cohort found no significant difference in CD4+ or CD8+ T-cell recovery with or without the peptide.[4]

Other peptides people research for immune system

All peptides for immune system, compared

Common questions

Does Thymosin Alpha-1 help with immune system?

The strongest study we summarise for immune system is human rct evidence, across 10 studies with an outcome for immune system. A trial result is not an approval; see the legal status.

Is Thymosin Alpha-1 approved for immune system?

No. Thymosin Alpha-1 is not FDA approved for any use, including immune system.

What is the best peptide for immune system?

There is no single answer. Our immune system overview compares each candidate by evidence grade and legal status rather than by popularity.

Does thymosin alpha 1 boost the immune system?

A phase 3 sepsis trial found no 28-day mortality difference (23.4% vs 24.1%), and a COVID-19 cohort found no difference in T-cell recovery.[1]

Is thymosin alpha 1 good for autoimmune disease?

MedlinePlus describes autoimmune disease as the immune system attacking healthy cells. The thymosin alpha 1 papers cited here studied sepsis and COVID-19, not autoimmune disease.[12]

Did thymosin alpha 1 work for COVID-19?

The evidence conflicts: one meta-analysis found lower COVID-19 mortality with thymosin alpha-1 and another found no significant effect.[9]

How does thymosin alpha 1 act on the immune system?

A hepatitis B review reports that in vitro studies show the peptide (Talpha1) can influence T-cell production and maturation, stimulate Th1 cytokines such as interferon-gamma and interleukin-2, and activate natural killer cell-mediated cytotoxicity; these are laboratory findings, not trial results.[13]

More on Thymosin Alpha-1

Sources

  1. 1The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
  2. 2Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
  3. 3Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.Frontiers in immunology · 2021PMID 34408744Accessed 2 Oct 2026
  4. 4Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.Frontiers in immunology · 2021PMID 34149679Accessed 2 Oct 2026
  5. 5Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.International immunopharmacology · 2020PMID 32795897Accessed 2 Oct 2026
  6. 6Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
  7. 7Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2025PMID 40969554Accessed 2 Oct 2026
  8. 8The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.Inflammopharmacology · 2023PMID 37845598Accessed 2 Oct 2026
  9. 9Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.International immunopharmacology · 2023PMID 36527881Accessed 2 Oct 2026
  10. 10The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.BMC infectious diseases · 2016PMID 27633969Accessed 2 Oct 2026
  11. 11Official web pageOfficial web page · web page
  12. 12medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  13. 13Thymalfasin for the treatment of chronic hepatitis B.Expert review of anti-infective therapy · 2004PMID 15482167Accessed 2 Oct 2026

Found an error? Report a correction.